Clinical Trials

Dermatologic

Melanoma

NCT05590221 2024-01-08

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Lymphoma, B-Cell

NCT06182735 2023-12-27

CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma

9 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06160362 2023-12-07

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

29 enrolled

Leukemia, Myeloid, Acute

NCT04825496 2023-09-21

Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04217278 2023-05-10

COSI

Phase 2/3 Unknown

333 enrolled

Leukemia, Myeloid, Acute

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrence, Lymphoma, B-Cell

NCT05798546 2023-04-04

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

21 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05776407 2023-03-20

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Lymphoma, B-Cell

NCT03467256 2023-02-24

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05727683 2023-02-14

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

33 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05322330 2023-02-09

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

NCT04706936 2023-02-06

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

25 enrolled

Multiple Myeloma, Recurrence

NCT05665114 2023-01-03

Natural Killer(NK) Cell Therapy in r/r AML

Leukemia, Myeloid, Acute

NCT05654077 2022-12-19

EBV CAR-T Cells for Nasopharyngeal Carcinoma

24 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05616468 2022-12-15

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

23 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05640713 2022-12-07

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited

NCT01946373 2022-10-04

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Dermatologic

Melanoma

NCT05515185 2022-08-25

B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors

30 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03692663 2022-08-01

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

9 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05122221 2022-06-28

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms

NCT05379647 2022-05-18

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

24 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT05322733 2022-04-19

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

25 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05287984 2022-03-31

ZFCR/ZBR

63 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04823091 2022-03-16

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

24 enrolled

Leukemia, T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell

NCT04112589 2022-03-14

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

63 enrolled

Leukemia, Myeloid, Acute

NCT05155215 2021-12-13

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

68 enrolled

Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, Mantle-Cell

NCT05008536 2021-11-23

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

27 enrolled

Multiple Myeloma

NCT04716114 2021-11-02

ALIVE

Phase 3 Unknown

315 enrolled

Leukemia, Myeloid, Acute

NCT05084027 2021-10-27

Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

Hematologic Neoplasms

NCT03257241 2021-10-01

PALG-AML1/2016

Phase 3 Unknown

582 enrolled

Leukemia, Myeloid, Acute

NCT03943472 2021-08-31

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

10 enrolled

Multiple Myeloma

NCT05016063 2021-08-23

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

32 enrolled

Leukemia, Myeloid, Acute

NCT03814447 2021-08-10

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

10 enrolled

Gynecologic

Ovarian Neoplasms

NCT04264078 2021-06-28

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

30 enrolled

Leukemia, T-Cell, Lymphoma, T-Cell

NCT04796675 2021-04-08

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

27 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04653493 2021-03-19

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

22 enrolled

Burkitt Lymphoma

NCT04796688 2021-03-15

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00790413 2021-02-21

Haploidentical Stem Cell Transplantation in Neuroblastoma

15 enrolled

CNS

Neuroblastoma

NCT04626726 2020-11-13

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Burkitt Lymphoma

NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Recurrence

NCT04626765 2020-11-13

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03380039 2020-10-12

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

6 enrolled

Multiple Myeloma

NCT03302403 2020-10-08

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

GastrointestinalLymphoidOther hematologic neoplasmPlasma cell

Carcinoma, Hepatocellular, Pancreatic Neoplasms, Leukemia, B-Cell, Lymphoma, B-Cell, Neoplasms, Plasma Cell

NCT03716856 2020-10-08

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

11 enrolled

Multiple Myeloma

NCT04221971 2020-10-01

NK Cell Infusion for Patients With Acute Myeloid Leukemia

10 enrolled

Leukemia, Myeloid, Acute

NCT03648697 2020-08-11

EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC

Head & Neck

Nasopharyngeal Carcinoma

NCT03778619 2020-07-28

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

9 enrolled

Lymphoma, Non-Hodgkin

NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy